NuVasive(R) Announces New Office Opening in Japan

NuVasive(R) Announces New Office Opening in Japan 
SAN DIEGO, CA -- (Marketwired) -- 04/24/13 --  NuVasive, Inc.
(NASDAQ: NUVA), a medical device company focused on developing
minimally disruptive surgical products and procedures for the spine,
is pleased to announce the official opening of its Tokyo, Japan
office, which will strengthen the Company's ability to bring
game-changing products, procedures, and services to the second
largest spine market in the world.  
The Tokyo office will be headed by NuVasive's Executive Vice
President of Asia Pacific, Takaaki Tanaka. Tanaka-san has been with
the Company since 2009, and brings an extensive 20 years of
experience in the spine industry. 
"NuVasive's formal presence in Tokyo is a testament to our commitment
to surgeon customers and their patients in Japan. We look forward to
improving patient outcomes with superior clinical results as we
further introduce XLIF(R) and our comprehensive spine portfolio to
the Japanese market," said Takaaki Tanaka. 
NuVasive recently completed several of the first eXtreme Lateral
Interbody Fusion (XLIF(R)) surgical procedures in key cities and
markets as a minimally disruptive option for lumbar spine fusion to
patients and surgeons in Japan.  
"This marks an exciting moment in NuVasive history," said Alex
Lukianov, Chairman and CEO of NuVasive. "I am especially pleased to
formally open our Tokyo office. As a company, we bring a wealth of
experience in spine, with proprietary innovative procedures like
XLIF(R) and procedurally integrated solutions. Our initial reception
in Japan has been exceptional, and I look forward to working with
Tanaka-san and Russell Powers, our Executive Vice President of
International, to improve spine surgery in one of the world's largest
spine markets."  
With eight international offices located in Europe, Australia, and
Asia, NuVasive has a presence in over 35 countries to facilitate the
proliferation of the Company's Culture of Speed of Innovation and
Absolute Responsiveness on a global basis. 
About XLIF(R):
 XLIF(R) is a minimally disruptive surgical procedure
performed through the side of the body utilizing proprietary
neuromonitoring and an integrated portfolio of instruments and
specialized implants for treating a range of spinal pathologies. 
For NuVasive Press Materials please visit:
http://www.nuvasive.com/about-us/newsroom/ 
About NuVasive
 NuVasive is a medical device company focused on
developing minimally disruptive surgical products and procedurally
integrated solutions for the spine. The Company is the 4th largest
player in the $8.2 billion global spine market. NuVasive's principal
product offering is based on its Maximum Access Surgery, or MAS(R)
platform. The MAS platform combines several categories of solutions
that collectively minimize soft tissue disruption during spine
surgery with maximum visualization and safe, easy reproducibility for
the surgeon: a proprietary software-driven nerve avoidance system and
intra-operative monitoring support; MaXcess(R), a unique split-blade
retractor system; a wide variety of specialized implants; and several
biologic products to aid in the spinal fusion process. MAS
significantly reduces surgery time and returns patients to activities
of daily living much faster than conventional approaches. Having
redefined spine surgery with the MAS platform's lateral approach,
known as eXtreme Lateral Interbody Fusion, or XLIF(R), NuVasive has
built an entire spine franchise. With over 80 products today spanning
lumbar, thoracic and cervical applications, the Company will continue
to expand and evolve its offering predicated on its R&D focus and
dedication to outstanding service levels supported by a culture of
Absolute Responsiveness(R).  
NuVasive cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical results
or those expressed or implied by such forward-looking statements. The
potential risks and uncertainties are described in NuVasive's press
releases and periodic filings with the Securities and Exchange
Commission. NuVasive's public filings with the Securities and
Exchange Commission are available at www.sec.gov. NuVasive assumes no
obligation to update any forward-looking statement to reflect events
or circumstances arising after the date on which it was made. 
Investor Contact:
Stephan Ogilvie 
VP, Corporate Development & Investor Relations
NuVasive, Inc.
201-322-6515
investorrelations@nuvasive.com 
Media: 
Nicole Collins
NuVasive, Inc.
858-909-1907
media@nuvasive.com 
 
 
Press spacebar to pause and continue. Press esc to stop.